Table 1 Demographic and professional characteristic of participants
| Â | Number (%) |
|---|---|
Age, mean (SD), n = 249 | 45.2 (11.6) |
Men, n = 266 | 172 (64.7) |
Country, n = 262 | |
 ➣ USA | 47 (18) |
 ➣ UK | 32 (12.2) |
 ➣ Italy | 23 (8.7) |
 ➣ Netherlands | 16 (6.1) |
 ➣ Canada | 16 (6.1) |
 ➣ Australia | 15 (5.7) |
 ➣ Brazil | 12 (4.6) |
 ➣ Others –each country less than all mentioned above – | 101 (38.6) |
Continent, n = 262 | |
 ➣ WHO Eastern Mediterranean Region | 12 (4.6) |
 ➣ WHO European Region | 136 (52) |
 ➣ WHO African Region | 2 (0.8) |
 ➣ WHO Region of the Americas | 75 (28.6) |
 ➣ WHO South-East Asia Region | 8 (3.1) |
 ➣ WHO Western Pacific Region | 29 (11.1) |
Years of experience in SR/MA, mean (SD), n = 265 | 9.2 (6.3) |
Main research interest of SR/MA, n = 264 | |
 ➣ Clinical trial | 130 (49.2) |
 ➣ Epidemiology | 43 (16.2) |
 ➣ Diagnostic accuracy | 18 (6.8) |
 ➣ Basic science (such as in vitro study) | 14 (5.3) |
 ➣ Genetic association | 9 (3.4) |
 ➣ Other | 50 (18.9) |
Number of publications in SR/MA, mean (SD), n = 263 | 15.1 (52.2) |
| Â | N (%) |
 ➣ 1–10 | 190 (72.2) |
 ➣ 10–50 | 63 (24) |
 ➣ 50–100 | 7 (2.7) |
 ➣  > 100 | 3 (1.1) |
Highest Impact Factor Journal of your publications in SR/MA, n = 267 | |
 ➣ 0–2 | 36 (13.6) |
 ➣ 2–5 | 84 (31.5) |
 ➣ 5–10 | 76 (28.5) |
 ➣ 10–20 | 30 (11.4) |
 ➣ > 20 | 15 (5.6) |
 ➣ Do not know | 26 (9.7) |